XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net income $ 31,698 $ 68,936
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 5,558 3,844
Provision for doubtful accounts 14 104
Non-cash interest expense 7,156 2,722
Loss on partial settlement of convertibles notes 56,369 0
Deemed repayment of convertible notes attributable to accreted debt discount (15,579) 0
Change in fair value of debt security (1,437) 0
Stock-based compensation 14,844 7,515
Change in fair value of derivatives 0 (15,344)
Deferred income taxes (35,367) (12,500)
Changes in operating assets and liabilities:    
Accounts receivable (53,719) 49,637
Inventory 6,888 (2,560)
Prepaid expenses and other assets (5,040) (5,009)
Accounts payable, accrued and other liabilities 36,376 (22,066)
Warranty obligations 8,640 403
Deferred revenues 19,440 (36,460)
Net cash provided by operating activities 75,841 39,222
Cash flows from investing activities:    
Purchases of property and equipment (9,940) (3,353)
Investment in a private company (25,000) 0
Business acquisitions, net of cash acquired (55,239) 0
Net cash used in investing activities (90,179) (3,353)
Cash flows from financing activities:    
Issuance of convertible notes, net of issuance costs 1,189,388 313,011
Purchase of convertible note hedges (286,235) (89,056)
Sale of warrants 220,800 71,552
Principal payments and financing fees on debt (1,078) (1,148)
Partial repurchase of convertible notes (289,233) 0
Proceeds from exercise of equity awards and employee stock purchase plan 214 1,979
Payment of withholding taxes related to net share settlement of equity awards (9,185) (34,267)
Net cash provided by financing activities 824,671 262,071
Effect of exchange rate changes on cash and cash equivalents (702) (205)
Net increase in cash, cash equivalents and restricted cash 809,631 297,735
Cash, cash equivalents and restricted cash—Beginning of period 679,379 296,109
Cash. cash equivalents and restricted cash—End of period 1,489,010 593,844
Supplemental disclosures of non-cash investing and financing activities:    
Total cash, cash equivalents, and restricted cash 1,489,010 593,844
Purchases of fixed assets included in accounts payable 7,301 585
Contingent consideration in connection with the acquisition 3,500 0
Convertible senior note issuance costs included in accounts payable and accrued expense $ 991 $ 591